knowledge -WSS

knowledge

author：explore 2025-09-03 03:22:58 - browse：89

Boston Globe

A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and pediatricians to scramble for alternatives just as allergy season is about to start.

In a move unusual for such a widely used drug, GlaxoSmithKline discontinued Flovent HFA, the brand name of its corticosteroid treatment fluticasone propionate, at the end of December. Critics, including Massachusetts Senator Elizabeth Warren, say the decision helps the company avoid new Medicaid penalties going into effect this year for medications with price increases that outpace inflation.

“It was all very confusing, and we were left scrambling, trying to find out what we could do,” said Simone Fung, whose 5-year-old son, David, endured worse asthma symptoms over the past two months as the Cambridge family navigated confusing insurance policies and shortages of alternative medications to find a replacement for Flovent.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Novel spinal cord stimulator treats paralysis without surgery

explore

WSS

New oral drug delivery patch is modeled after octopus tentacles

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Crowdfunding for medical bills sidesteps core problem, author says

Brain MRIs reveal impact of 'toxic stress' on Black children

RSV injection headlines need to be accurate for good uptake

Flu, Covid vaccination rates decline, new survey data show

hotspot

knowledge

entertainment

What does generative AI mean for health care? We asked experts

Welsh Carson private equity firm escapes from FTC antitrust case

Guidelines to prevent youth baseball injuries need more muscle

Has Bernie Sanders reached the limit of his pharma bullying effort?

As demand for Covid shots wanes, Moderna seeks its next success

As billionaires fund anti

Moonlake's readout produced a cash windfall. Risks remain

Setback for rare diseases as Taysha Gene Therapies pulls back

Activists slam private health insurers over coverage restrictions

Medicare innovation center doesn’t save money, experts say

Wikipedia

CRISPR base editing slashes cholesterol levels in monkeys

The effects of a landmark ruling on DNA ownership are becoming clearer

Primary care doctor shortage won't be solved by free med school tuition

AltruBio raises $225 million to develop ulcerative colitis drug

Crowdfunding for medical bills sidesteps core problem, author says

Study points to new risk in gene therapy death of Terry Horgan

explore

focus

explore

leisure time